Cardiothoracic & vascular anesthesia
Influence of Fibrinogen Concentrate on Neonatal Clot Structure When Administered Ex Vivo After Cardiopulmonary Bypass
Authors' conclusion
Our results show that clots formed ex vivo with clinically relevant doses of FC (0.9 mg/mL) display similar structural and degradation characteristics compared to the in vivo transfusion of cryoprecipitate.
Study context
- Population
- Neonates undergoing cardiac surgery with CPB
- Comparison
- Post-CPB plasma +0.5 or +0.9 mg/mL fibrinogen concentrate (FC) vs untreated post-CPB plasma and post-transfusion of cryoprecipitate
- Outcome
- Fiber density
Methodological detailsex vivo
- Ex vivo
Main finding
As reported in the abstract
Post-CPB
0.44
median · IQR 0.36–0.52
Post-CPB +0.5 mg/mL FC
0.69
median · IQR 0.56–0.77
Post-CPB +0.9 mg/mL FC
0.87
median · IQR 0.59–0.96
Post-transfusion
0.54
median · IQR 0.45–0.77
Post-CPB +0.5 mg/mL FC vs Post-CPB: P = 0.01 · Post-CPB +0.9 mg/mL FC vs Post-CPB: P = 0.006 · Post-CPB +0.9 mg/mL FC vs Post-transfusion: P = 0.002
Further findings
Fiber alignment
- Median fiber alignment did not differ significantly between post-CPB and FC-treated samples
Degradation rate
- Not statistically significant from baseline with either 0.5 or 0.9 mg/mL FC
Baseline–post-CPB fibrinogen concentration difference vs patient age
- Significant correlation with patient age after controlling for weight
- P = 0.033
Original publication
Composed by AI from the published abstract and checked against it. How Briefs are made →